Xgene Corporation was founded from technology developed at Stanford University for producing a full-thickness human skin equivalent, CeSSE (Cell-Sorted Skin Equivalent), pronounced "cease." This acronym has special meaning in light of worldwide legislation mandating the cessation of animal testing. Xgene's skin model has immediate application as a substitute for animal testing, and so Xgene is uniquely positioned to take advantage of a lucrative new market. CeSSE skin has broad applications in the cosmetics, personal care, and other consumer products industries and therefore there is an immediate need for human skin for testing and future grafting. This, in combination with medical application in wound healing and disease, has created tremendous demand for our products and services. In addition to an exclusive license for its basic CeSSE skin technology, Xgene also has multiple patents pending on enhancements of this technology
